Mission Street have established a market-leading and rapidly growing Science and Innovation platform.
The current portfolio comprises over 1.5 million sq ft of committed projects in key strategic locations within Oxford, Cambridge and Bristol. Our innovative schemes and campuses are being developed speculatively with the first phases being the next available lab space in the respective locations.
Mission Street was founded in 2017 as an independent investor, developer and operator of Science and Innovation real estate. The company has since established itself as an industry leader working in conjunction with a highly experienced Advisory Board who bring invaluable insight and expertise from the perspective of our customers.
The current portfolio comprises over 1.5 million sq ft of committed projects in key strategic locations within Oxford, Cambridge and Bristol. Our innovative schemes and campuses are being developed speculatively with the first phases being the next available lab space in the respective locations.
Mission Street was founded in 2017 as an independent investor, developer and operator of Science and Innovation real estate. The company has since established itself as an industry leader working in conjunction with a highly experienced Advisory Board who bring invaluable insight and expertise from the perspective of our customers.
Drug Discovery
Clinical stage drug development company, bringing a stratified approach to neuroscience drug repurposing using digital biomarkers
Mursla is a startup developing a diagnostic device that leverages proprietary nanostructures to significantly improve cancer detection through the utilization of a novel, non-invasive procedure called liquid biopsy.
No data available
NanoSyrinx is a discovery stage biotechnology company based at the University of Warwick Science Park. We are using synthetic biology approaches to develop a completely novel modality for the targeted, intracellular delivery of therapeutic proteins and peptides.
No data available
No data available
NEB UK supplies a broad range of reagents and kits for basic and applied research at the DNA, RNA and protein levels. These products are also for use in drug development and screening, as well as for use in platform technologies and as raw materials in kit manufacture. We supply standard catalogue products as well as custom and bulk formulations. We would like to partner with you from R&D downstream to market. Call us to discuss your ‘biological component’ needs.
New Path Molecular specialises in the chemical synthesis of complex functional molecules using the cutting edge techniques, methods and instrumentation developed in the laboratories of Prof Steve Ley at the University of Cambridge. Our processes and molecules are being used to validate biological processes and produce products globally.